Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit
Novartis beat Q3 adjusted earnings estimates despite a $1.9 billion Avidity impairment charge, lifted by strong sales of Kisqali, Kesimpta, and revised guidance.
Share
Why It Matters
Novartis had to write down one investment by $1.9 billion. But their popular medicines sold well, so they still beat expectations and feel good about the future.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.